Biological basis of therapy

New molecular targets

Terry H Landowski, William S. Dalton

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Traditionally, the design of cytotoxic agents used for the treatment of malignant disease has attempted to take advantage of unique biochemical characteristics of the tumor cell. For example, many of the most potent cytotoxic agents act at specific stages of the cell cycle and are most effective in tumors with a large growth fraction. Although the systemic toxicity of these agents is often quite high, this approach has produced treatment regimens with curative results in many tumor types. In contrast, multiple myeloma remains an incurable disease with a median survival of 30-40 months. The major obstacle to successful treatment of myeloma is the emergence of drug-resistant disease. Although 50-60% of patients initially respond to standard chemotherapeutic regimens, essentially all patients ultimately relapse with tumor that is refractory to further treatment. Recent advances in molecular genetics have provided the means to identify tumor-specific pathways that regulate myeloma cell growth and survival. Furthermore, in a revival of the ‘seed and soil’ hypothesis,1 the contribution of the tumor microenvironment to the growth and survival of malignant cells has identified tumorcell interactions with the microenvironment as a potential point of therapeutic intervention. Identification of the molecular mechanisms contributing to tumor cell survival and the pathways involved are providing fertile ground for the development of molecular inhibitors with high tumor specificity and low systemic toxicity.

Original languageEnglish (US)
Title of host publicationMultiple Myeloma and Related Disorders
PublisherCRC Press
Pages292-304
Number of pages13
ISBN (Electronic)9781444114140
ISBN (Print)9780340810101
StatePublished - Jan 1 2004

Fingerprint

Biological Therapy
Neoplasms
Cell Survival
Cytotoxins
Growth
Therapeutics
Tumor Microenvironment
Multiple Myeloma
Molecular Biology
Seeds
Cell Cycle
Soil
Recurrence
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Landowski, T. H., & Dalton, W. S. (2004). Biological basis of therapy: New molecular targets. In Multiple Myeloma and Related Disorders (pp. 292-304). CRC Press.

Biological basis of therapy : New molecular targets. / Landowski, Terry H; Dalton, William S.

Multiple Myeloma and Related Disorders. CRC Press, 2004. p. 292-304.

Research output: Chapter in Book/Report/Conference proceedingChapter

Landowski, TH & Dalton, WS 2004, Biological basis of therapy: New molecular targets. in Multiple Myeloma and Related Disorders. CRC Press, pp. 292-304.
Landowski TH, Dalton WS. Biological basis of therapy: New molecular targets. In Multiple Myeloma and Related Disorders. CRC Press. 2004. p. 292-304
Landowski, Terry H ; Dalton, William S. / Biological basis of therapy : New molecular targets. Multiple Myeloma and Related Disorders. CRC Press, 2004. pp. 292-304
@inbook{3301a577bd854dccbf5c6ecb8ecaa537,
title = "Biological basis of therapy: New molecular targets",
abstract = "Traditionally, the design of cytotoxic agents used for the treatment of malignant disease has attempted to take advantage of unique biochemical characteristics of the tumor cell. For example, many of the most potent cytotoxic agents act at specific stages of the cell cycle and are most effective in tumors with a large growth fraction. Although the systemic toxicity of these agents is often quite high, this approach has produced treatment regimens with curative results in many tumor types. In contrast, multiple myeloma remains an incurable disease with a median survival of 30-40 months. The major obstacle to successful treatment of myeloma is the emergence of drug-resistant disease. Although 50-60{\%} of patients initially respond to standard chemotherapeutic regimens, essentially all patients ultimately relapse with tumor that is refractory to further treatment. Recent advances in molecular genetics have provided the means to identify tumor-specific pathways that regulate myeloma cell growth and survival. Furthermore, in a revival of the ‘seed and soil’ hypothesis,1 the contribution of the tumor microenvironment to the growth and survival of malignant cells has identified tumorcell interactions with the microenvironment as a potential point of therapeutic intervention. Identification of the molecular mechanisms contributing to tumor cell survival and the pathways involved are providing fertile ground for the development of molecular inhibitors with high tumor specificity and low systemic toxicity.",
author = "Landowski, {Terry H} and Dalton, {William S.}",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780340810101",
pages = "292--304",
booktitle = "Multiple Myeloma and Related Disorders",
publisher = "CRC Press",

}

TY - CHAP

T1 - Biological basis of therapy

T2 - New molecular targets

AU - Landowski, Terry H

AU - Dalton, William S.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Traditionally, the design of cytotoxic agents used for the treatment of malignant disease has attempted to take advantage of unique biochemical characteristics of the tumor cell. For example, many of the most potent cytotoxic agents act at specific stages of the cell cycle and are most effective in tumors with a large growth fraction. Although the systemic toxicity of these agents is often quite high, this approach has produced treatment regimens with curative results in many tumor types. In contrast, multiple myeloma remains an incurable disease with a median survival of 30-40 months. The major obstacle to successful treatment of myeloma is the emergence of drug-resistant disease. Although 50-60% of patients initially respond to standard chemotherapeutic regimens, essentially all patients ultimately relapse with tumor that is refractory to further treatment. Recent advances in molecular genetics have provided the means to identify tumor-specific pathways that regulate myeloma cell growth and survival. Furthermore, in a revival of the ‘seed and soil’ hypothesis,1 the contribution of the tumor microenvironment to the growth and survival of malignant cells has identified tumorcell interactions with the microenvironment as a potential point of therapeutic intervention. Identification of the molecular mechanisms contributing to tumor cell survival and the pathways involved are providing fertile ground for the development of molecular inhibitors with high tumor specificity and low systemic toxicity.

AB - Traditionally, the design of cytotoxic agents used for the treatment of malignant disease has attempted to take advantage of unique biochemical characteristics of the tumor cell. For example, many of the most potent cytotoxic agents act at specific stages of the cell cycle and are most effective in tumors with a large growth fraction. Although the systemic toxicity of these agents is often quite high, this approach has produced treatment regimens with curative results in many tumor types. In contrast, multiple myeloma remains an incurable disease with a median survival of 30-40 months. The major obstacle to successful treatment of myeloma is the emergence of drug-resistant disease. Although 50-60% of patients initially respond to standard chemotherapeutic regimens, essentially all patients ultimately relapse with tumor that is refractory to further treatment. Recent advances in molecular genetics have provided the means to identify tumor-specific pathways that regulate myeloma cell growth and survival. Furthermore, in a revival of the ‘seed and soil’ hypothesis,1 the contribution of the tumor microenvironment to the growth and survival of malignant cells has identified tumorcell interactions with the microenvironment as a potential point of therapeutic intervention. Identification of the molecular mechanisms contributing to tumor cell survival and the pathways involved are providing fertile ground for the development of molecular inhibitors with high tumor specificity and low systemic toxicity.

UR - http://www.scopus.com/inward/record.url?scp=27144545708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144545708&partnerID=8YFLogxK

M3 - Chapter

SN - 9780340810101

SP - 292

EP - 304

BT - Multiple Myeloma and Related Disorders

PB - CRC Press

ER -